University of Southampton, Southampton, UK.
Cardiology, University Hospital Southampton NHS Trust, Southampton, UK.
Heart. 2023 Nov 10;109(23):1772-1777. doi: 10.1136/heartjnl-2023-322463.
Cardiac troponin (cTn) concentrations above the manufacturer recommended upper limit of normal (ULN) are frequently seen in hospital patients without a clinical presentation consistent with type 1 myocardial infarction, and the significance of this is uncertain. The aim of this study was to assess the relationship between medium-term mortality and cTn concentration in a large consecutive hospital population, regardless of whether there was a clinical indication for performing the test.
This prospective observational study included 20 000 consecutive in-hospital and outpatient patients who had a blood test for any reason at a large teaching hospital, and in whom a hs-cTnI assay was measured, regardless of the original clinical indication. Mortality was obtained via NHS Digital.
A total of 20 000 patients were included in the analysis and 18 282 of these (91.4%) did not have a clinical indication for cardiac troponin I (cTnI) testing. Overall, 2825 (14.1%) patients died at a median of 809 days. The mortality was significantly higher if the cTnI concentration was above the ULN (45.3% vs 12.3% p<0.001 log rank). Multivariable Cox analysis demonstrated that the log cTnI concentration was independently associated with mortality (HR 1.76 (95% CI 1.65 to 1.88)). Landmark analysis, excluding deaths within 30 days, showed the relationship between cTnI concentration and mortality persisted.
In a large, unselected hospital population, in 91.4% of whom there was no clinical indication for testing, cTnI concentration was independently associated with medium-term cardiovascular and non-cardiovascular mortality in the statistical model tested.
在没有临床表现符合 1 型心肌梗死的住院患者中,经常会发现心脏肌钙蛋白(cTn)浓度高于制造商建议的正常值上限(ULN),其意义尚不确定。本研究旨在评估在一个大型连续住院和门诊人群中,无论是否有进行该检测的临床指征,cTn 浓度与中期死亡率之间的关系。
本前瞻性观察性研究纳入了 20000 例因任何原因在一家大型教学医院进行血液检测的连续住院和门诊患者,无论最初的临床指征如何,均测量高敏肌钙蛋白 I(hs-cTnI)检测。通过 NHS Digital 获得死亡率。
共有 20000 例患者纳入分析,其中 18282 例(91.4%)无心脏肌钙蛋白 I(cTnI)检测的临床指征。总体而言,中位数为 809 天的有 2825 例(14.1%)患者死亡。如果 cTnI 浓度高于 ULN,死亡率显著更高(45.3%比 12.3%,p<0.001,对数秩检验)。多变量 Cox 分析表明,cTnI 浓度与死亡率独立相关(HR 1.76(95%CI 1.65 至 1.88))。排除 30 天内死亡的时间标记分析显示,cTnI 浓度与死亡率之间的关系仍然存在。
在一个大型、未选择的医院人群中,在 91.4%的患者中没有检测的临床指征,在测试的统计模型中,cTnI 浓度与中期心血管和非心血管死亡率独立相关。